NOを放出するゼオライトとその抗血栓性特性
Paul S Wheatley1, Anthony R Butler, Michael S Crane
1School of Chemistry, University of St. Andrews, Purdie Building, UK.
Journal of the American Chemical Society
|January 13, 2006
まとめ
移行金属交換ゼオライト-Aは,窒素酸化物 (NO) を効果的に貯蔵し,水に放出します. このNOの放出は血小板の集約を阻害し,医学的な応用の可能性を示しています.
科学分野:
- マテリアルサイエンス 材料科学
- バイオメディカルエンジニアリング
- 化学 化学は化学です.
背景:
- ゼオライトAは,分子を吸収し,貯蔵することができます.
- 酸化窒素 (NO) は生物学的シグナル伝達機能を持っています.
- NOの制御された放出は,治療的な用途のために望ましい.
研究 の 目的:
- 酸化窒素 (NO) の吸収と貯蔵のための移行金属交換ゼオライト-Aの能力を調査する.
- 貯蔵されたNOの制御された放出のための条件と方法を探求する.
- 放出されたNOの生物学的活性,特にヒトの血小板への影響を評価する.
主な方法:
- 移行金属交換ゼオライト-A.A.の合成と特徴付け
- 制御された条件下でNOの吸収と貯蔵.
- 水性環境によって引き起こされるNO放出に関するインビトロ研究.
- NOが血小板の集積と粘着に及ぼす影響の評価.
主要な成果:
- ゼオライトAは高いNO吸収能力 (最大1mmol NO/g) を示した.
- NOの放出は,生物学的に関連する温度とpHの水溶液との接触で観察されました.
- 放出運動は,ゼオライトの組成,水との接触,およびポリマー混合を改変することによって調整可能であった.
- 同交換ゼオライト-Aは,ヒトの血小板の集積と粘着を in vitro で抑制する NO を放出します.
結論:
- 移行金属交換ゼオライト-Aは,高容量のNO貯蔵のための有望な材料です.
- ゼオライトAからのNOの制御された放出は,特定の用途のために調節することができます.
- 放出されるNOの観察された抗血小板活性が,血栓形成および血静性における潜在的な治療用途を示唆しています.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...